Blueprint Medicines (BPMC) reported a Q4 net loss Thursday of $0.79 per diluted share, narrowing from a loss of $1.82 a year earlier.

Analysts polled by FactSet expected a loss of $0.67.

Revenue for the quarter ended Dec. 31, 2024, was $146.4 million, up from $72 million a year earlier.

Analysts surveyed by FactSet expected $146 million.

The company's shares were down nearly 9% in recent Thursday premarket activity.

Price: 94.50, Change: -9.06, Percent Change: -8.8